Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis

Respiratory Medicine

Volumn 109, Issue 9, 2015, Pages 1174-1180

  Takada, Toshinori ^a   Aoki, Ami ^a   Asakawa, Katsuaki ^a   Sakagami, Takuro ^a   Moriyama, Hiroshi ^a   Narita, Ichiei ^a   Sato, Shinji ^b  

^a NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemokine CX3CL1; Cytokine; Dermatomyositis; Interstitial lung disease

Indexed keywords

ALPHA2 INTERFERON; ANTIBODY; CADM 140 ANTIBODY; CYTOKINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; FMS LIKE TYROSINE KINASE; FRACTALKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MDA5 ANTIBODY; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; AUTOANTIBODY; BIOLOGICAL MARKER; CADM-140 PEPTIDE, HUMAN; DEAD BOX PROTEIN; IFIH1 PROTEIN, HUMAN; PEPTIDE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DERMATOMYOSITIS; DISEASE ASSOCIATION; FEMALE; GROWTH RELATED ONCOGENE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; ONCOGENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; IMMUNOLOGY; LUNG DISEASES, INTERSTITIAL; PROGNOSIS; RADIOGRAPHY; RETROSPECTIVE STUDY;

ADULT; AGED; AUTOANTIBODIES; BIOMARKERS; CYTOKINES; DEAD-BOX RNA HELICASES; DERMATOMYOSITIS; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PEPTIDES; PROGNOSIS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84941695069     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2015.07.004     Document Type: Article

References (42)

1. M.C. Dalakas, and R. Hohlfeld Polymyositis and dermatomyositis Lancet 362 2003 971 982 [PMID: 14511932
2. I. Marie, P.Y. Hatron, S. Dominique, and et al. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients Arthritis Rheum. 63 2011 3439 3447 [PMID: 21702020 10.1002/art.30513]
3. R.D. Sontheimer, and S. Miyagawa Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositis J. Am. Acad. Dermatol. 48 2003 797 798 [PMID: 12734516
4. T. Suda, T. Fujisawa, N. Enomoto, and et al. Interstitial lung diseases associated with amyopathic dermatomyositis Eur. Respir. J. 28 2006 1005 1012 [PMID: 16837503
5. N. Sakamoto, H. Mukae, T. Fujii, and et al. Nonspecific interstitial pneumonia with poor prognosis associated with amyopathic dermatomyositis Intern. Med. 43 2004 838 842 [PMID: 15497521
6. W.A. High, J.B. Cohen, B.A. Murphy, and et al. Fatal interstitial pulmonary fibrosis in anti-Jo-1-negative amyopathic dermatomyositis J. Am. Acad. Dermatol. 49 2003 295 298 [PMID: 12894081
7. E.H. Kang, E.B. Lee, K.C. Shin, and et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis Rheumatol. Oxf. 44 2005 1282 1286 [PMID: 15972351
8. S. Sato, M. Hirakata, M. Kuwana, and et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis Arthritis Rheum. 52 2005 1571 1576 [PMID: 15880816 10.1002/art.21023]
9. S. Sato, K. Hoshino, T. Satoh, and et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease Arthritis Rheum. 60 2009 2193 2200 [PMID: 19565506 10.1002/art.24621]
10. S. Sato, M. Kuwana, T. Fujita, and et al. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies Mod. Rheumatol. 22 2012 625 629 [PMID: 22124544 10.1007/s10165-011-0558-9]
11. S. Sato, M. Kuwana, T. Fujita, and et al. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease Mod. Rheumatol. 23 2013 496 502 [PMID: 22644102 10.1007/s10165-012-0663-4]
12. Y. Muro, K. Sugiura, K. Hoshino, and et al. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission Rheumatol. Oxf. 51 2012 800 804 [PMID: 22210662 10.1093/rheumatology/ker408]
13. T. Koga, K. Fujikawa, Y. Horai, and et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM Rheumatol. Oxf. 51 2012 1278 1284 [PMID: 22378718 10.1093/rheumatology/ker518]
14. T. Gono, S. Sato, Y. Kawaguchi, and et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis Rheumatol. Oxf. 51 2012 1563 1570 [PMID: 22589330 10.1093/rheumatology/kes102]
15. H. Cao, M. Pan, Y. Kang, and et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody Arthritis Care Res. 64 2012 1602 1610 [PMID: 22623119 10.1002/acr.21728]
16. N. Sakurai, K. Nagai, H. Tsutsumi, and et al. Anti-CADM-140 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and cardiac involvement J. Rheumatol. 38 2011 963 964 [PMID: 21532064 10.3899/jrheum.101220]
17. I. Kobayashi, Y. Okura, M. Yamada, and et al. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis J. Pediatr. 158 2011 675 677 [PMID: 21232756 10.1016/j.jpeds.2010.11.033]
18. S.L. Tansley, Z.E. Betteridge, H. Gunawardena, and et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study Arthritis Res. Ther. 16 2014 R138 [PMID: 24989778 10.1186/ar4600]
19. D. Fiorentino, L. Chung, J. Zwerner, and et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study J. Am. Acad. Dermatol. 65 2011 25 34 [PMID: 21531040 10.1016/j.jaad.2010.09.016]
20. N.S. Narang, L. Casciola-Rosen, S. Li, and et al. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease Arthritis Care Res. 67 2015 667 672 [PMID: 25331610 10.1002/acr.22498]
21. G.I. Rice, Y. del Toro Duany, E.M. Jenkinson, and et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling Nat. Genet. 46 2014 503 509 [PMID: 24686847 10.1038/ng.2933]
22. A. Bohan, and J.B. Peter Polymyositis and dermatomyositis (first of two parts) N. Engl. J. Med. 292 1975 344 347 [PMID: 1090839
23. A. Arshanapalli, M. Shah, V. Veerula, and et al. The role of type I interferons and other cytokines in dermatomyositis Cytokine 73 2015 319 325 [PMID: 25541432 10.1016/j.cyto.2014.11.026]
24. T. Gono, H. Kaneko, Y. Kawaguchi, and et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease Rheumatol. Oxf. 53 2014 2196 2203 [PMID: 24970922 10.1093/rheumatology/keu258]
25. H. Kato, O. Takeuchi, E. Mikamo-Satoh, and et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5 J. Exp. Med. 205 2008 1601 1610 [PMID: 18591409 10.1084/jem.20080091]
26. M. Funabiki, H. Kato, Y. Miyachi, and et al. Autoimmune disorders associated with gain of function of the intracellular sensor MDA5 Immunity 40 2014 199 212 [PMID: 24530055 10.1016/j.immuni.2013.12.014]
27. M. Nakano, T. Fujii, M. Hashimoto, and et al. Type I interferon induces CX3CL1 (fractalkine) and CCL5 (RANTES) production in human pulmonary vascular endothelial cells Clin. Exp. Immunol. 170 2012 94 100 [PMID: 22943205 10.1111/j.1365-2249.2012.04638.x]
28. J.F. Bazan, K.B. Bacon, G. Hardiman, and et al. A new class of membrane-bound chemokine with a CX3C motif Nature 385 1997 640 644 [PMID: 9024663 10.1038/385640a0]
29. T. Imai, K. Hieshima, C. Haskell, and et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion Cell 91 1997 521 530 [PMID: 9390561
30. H. Nomiyama, T. Imai, J. Kusuda, and et al. Human chemokines fractalkine (SCYD1), MDC (SCYA22) and TARC (SCYA17) are clustered on chromosome 16q13 Cytogenet. Cell Genet. 81 1998 10 11 [PMID: 9691168
31. H. Umehara, E. Bloom, T. Okazaki, and et al. Fractalkine and vascular injury Trends Immunol. 22 2001 602 607 [PMID: 11698220
32. J.H. Ruth, M.V. Volin, G.K. Haines 3rd, and et al. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis Arthritis Rheum. 44 2001 1568 1581 [PMID: 11465708 10.1002/1529-0131(200107)44:7<1568::AID-ART280>3.0.CO;2-1]
33. T. Matsumiya, K. Ota, T. Imaizumi, and et al. Characterization of synergistic induction of CX3CL1/fractalkine by TNF-alpha and IFN-gamma in vascular endothelial cells: an essential role for TNF-alpha in post-transcriptional regulation of CX3CL1 J. Immunol. 184 2010 4205 4214 [PMID: 20231691 10.4049/jimmunol.0903212]
34. S.O. Moon, W. Kim, M.J. Sung, and et al. Resveratrol suppresses tumor necrosis factor-alpha-induced fractalkine expression in endothelial cells Mol. Pharmacol. 70 2006 112 119 [PMID: 16614140 10.1124/mol.106.022392]
35. T. Odai, M. Matsunawa, R. Takahashi, and et al. Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis J. Rheumatol. 36 2009 1158 1165 [PMID: 19369458 10.3899/jrheum.081074]
36. H. Okamoto, M. Yamamura, Y. Morita, and et al. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis Arthritis Rheum. 40 1997 1096 1105 [PMID: 9182920 10.1002/1529-0131(199706)40:6<1096::AID-ART13>3.0.CO;2-D]
37. F. Suzuki, T. Kubota, Y. Miyazaki, and et al. Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity Arthritis Res. Ther. 14 2012 R48 [PMID: 22394569 10.1186/ar3761]
38. T. Isozaki, K. Otsuka, M. Sato, and et al. Synergistic induction of CX3CL1 by interleukin-1beta and interferon-gamma in human lung fibroblasts: involvement of signal transducer and activator of transcription 1 signaling pathways Transl. Res. J. Lab. Clin. Med. 157 2011 64 70 [PMID: 21256458 10.1016/j.trsl.2010.11.007]
39. M. Hasegawa, S. Sato, T. Echigo, and et al. Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis Ann. Rheum. Dis. 64 2005 21 28 [PMID: 15608300 10.1136/ard.2003.018705]
40. A. De Lauretis, P. Sestini, P. Pantelidis, and et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis J. Rheumatol. 40 2013 435 446 [PMID: 23378460 10.3899/jrheum.120725]
41. W.W. Douglas, H.D. Tazelaar, T.E. Hartman, and et al. Polymyositis-dermatomyositis-associated interstitial lung disease Am. J. Respir. Crit. Care Med. 164 2001 1182 1185 [PMID
42. Y. Matsuki, H. Yamashita, Y. Takahashi, and et al. Diffuse alveolar damage in patients with dermatomyositis: a six-case series Mod. Rheumatol. 22 2012 243 248 [PMID: 21904785 10.1007/s10165-011-0502-z]